4
Changes in Ownership
Krystal Biotech, Inc. Filed Acc 0001860010-23-000004
Chief Commercial Officer sold 12,500 shares at an average $128.61 ($1,607,635)
- Chief Commercial Officer acquired 12,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
ORTH ANDREW C. · Chief Commercial Officer
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-06-09 | Exercise or conversion : show line 1 in the form 10b5-1 | +12,500 | $63.55 | $794,375 | 12,600 | D |
| 2023-06-09 | Sale : show line 2 in the form 10b5-1 | −5,261 | $128.10 | $673,958 | 7,339 | D |
| 2023-06-09 | Sale : show line 3 in the form 10b5-1 | −6,906 | $128.94 | $890,488 | 433 | D |
| 2023-06-09 | Sale : show line 4 in the form 10b5-1 | −333 | $129.70 | $43,189 | 100 | D |
| Open-market sales · 12,500 sh · avg $128.61 · $1,607,635 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-06-09 | Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) | −12,500 | 37,500 | D |
Loading xslF345X04/wk-form4_1686351600.xml…